CDL Hospitality trades at multi-month low levels $1.03 despite strong 2H outlook! (3 Sep 23)

September 3, 2023September 3, 2023 el15

Dear all CDL Hospitality Trust (CDREIT) has caught my attention after slumping from $1.19 on 31 Jul to close $1.03 on 31 Aug. After taking into account of $0.0251 dividend per share ex on 4 Aug, it is still down 11.6% for the month, notching a multi-month low despite a likely buoyant 2HFY23F. Let’s take a closer look on why CDREIT has caught my attention. Firstly, why did it drop 12% in Aug? The drop in CDREIT’s share price may be attributed to three main reasons, viz. a) 1HFY23 results missed some analysts’ estimates 1HFY23 results released on 28 […]

Fig 1_Lendlease reit average analyst target

Two charts – Lendlease Reit and Manulife US Reit caught my attention (11 Jul 23)

July 11, 2023 el15

Dear all, Based on my personal reading, since a couple of months ago, investor interest seems to be gradually rotating back into the reit sector. Several reits have caught my attention. For this write-up, I will focus on Lendlease Reit and Manulife US Reit. 1) Lendlease Reit closed $0.660 With reference to my write-up on Lendlease Reit dated 3 Jul 2023 (click HERE), I have compiled my key takeaways from my 1-1 meeting with Lendlease Reit’s management and from what I gather from the various analyst reports and my other readings into this write-up. As such, I will not be […]

Raffles Medical – Potential trading play as its results are just around the corner (20 Feb 23)

February 20, 2023 el15

Dear all, Raffles Medical caught my attention recently as CLSA raised its target price from $1.70 to $1.92 on 8 Feb 23. $1.92 is a street high target with most analysts’ target price ranging between $1.58 – 1.65. Raffles Medical closed down 1 cent to $1.45 last Fri. Based on my personal view and observation, generally speaking, analysts seldom issue updated call so near to the company’s results release date. I mean there is usually no such urgency to do so, unless they have a significant change in view on the company. For those analysts who do, their calls are […]

Tianjin Pharma – A potential undervalued company, net cash; rides on favourable tailwinds (24 Dec 22)

December 24, 2022 el15

Dear all Last Friday, personal protection equipment (“PPE”) and glovemakers rallied as much as 3% – 36% in a single day (See Table 1 below). This outperformance may be attributed to concerns that the Covid situation in China may worsen with more infections, or may cause the appearance of new variants, which may spur demand for gloves and personal protection equipment. Table 1: SG glovemakers and PPE share price performance on Friday Source: Ernest’s manual compilations 23 Dec 22 Personally, besides PPE and glovemakers which may benefit, Tianjin Pharmaceutical Da Ren Tang Group (“T14”) may be another potential and perhaps […]

Sunpower – price action & bullish divergence warrant a closer look (20 Dec 18)

December 20, 2018 el15

Dear readers, Some of you have sent me emails to express concerns whether I am still maintaining my blog, as I have not posted an article in the past couple of months. Thanks for the concern and emails. It warms my heart that there are readers who are actively following my blog. Something happened to my family which caused me unable to post articles on a timely basis. (My clients are still receiving some periodic short writeups on the market and specific companies during this period) Anyway, I am glad to be back to work this week! This week, Sunpower’s […]

Sing medical analyst target price 2 Oct 18

Sing Medical trades near one year low despite a 70% jump in 1HFY18 net profit! (3 Oct 2018)

October 3, 2018 el15

This week, Sing Medical (“SMG”) caught my attention. SMG has dropped 39% from $0.725 on 18 Jul 2017 to trade $0.440 on 3 Oct 2018. My personal guess is part of the fall may be attributable to a) Lower, or no earnings growth for some of the healthcare players in FY18F. However, this is likely not the case for SMG, as analysts believe SMG is on track for a minimum 40% growth in FY18F net profit. It is noteworthy that SMG already posted a 70% jump in 1HFY18 net profit; b) Reduction in the general PE valuations ascribed to the […]